4 research outputs found
ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΠΎΡΠ°Π³ΠΎΠ² Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΈΠΌΠΌΡΠ½Π½ΡΠΉ ΡΡΠ°ΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ
Objective: to study the influence of focal infection on the immune status of patients with psoriasis.Materials and methods. 30 patients with psoriasis aged 19 to 61 years (21 people β plaque psoriasis, 9 people β psoriasis guttata) were examined, which were divided into 2 groups. The first group β with the diagnosed of focal infection (18 people), the second group β without the presence of focal infection (12 people). The control group consisted of 15 healthy individuals admitted to the clinic for the removal of benign skin tumors. All patients underwent a comprehensive clinical, instrumental and laboratory examination, as well as an immunogram. Determination of lymphocyte subpopulations was carried out on a flow cytometer βCytom - ics FC500β by Beckman Coulter using various combinations of direct monoclonal antibodies and isotopic controls. The groups were compared using nonparametric Mann β Whitney test, the differences were considered significant at p 0.05.Results. The absence of significant quantitative changes in the main and small subpopulations of T- and Π-lymphocytes in both groups of patients with psoriasis was shown. At the same time, the group of patients with psoriasis and focal infection, was characterized by an increase in the relative number of T-lymphocytes (p = 0.034) and T-helpers (p = 0.012), the relative and absolute number of activated CD3+HLA-DR+cells (p = 0.028 and 0.036, respectively), as well as a decrease in regulatory T-helper (p = 0.031). Subpopulation of CLA+CD3+-lymphocytes tropic to the skin in comparison with control was increased both in the first (p = 0.016) and second (p = 0.044) groups. Also, patients with psoriasis differed from healthy individuals by increasing the number of memory T-cells (p = 0.049 for group 1, p = 0.003 for group 2).Conclusion. Existing focal infection in psoriasis patients lead to an imbalance in the content of individual lymphocyte subpopulations: an increase in the relative number of CD3+CD4+ and CD3+HLA-DR+ cells, as well as a decrease in regulatory T-helper. These changes can lead to a long course of the disease and a reduction in remission periods.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΡΠ°Π³ΠΎΠ² Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (ΠΠ₯Π) Π½Π° ΠΈΠΌΠΌΡΠ½Π½ΡΠΉ ΡΡΠ°ΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 30 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 19 Π΄ΠΎ 61 Π³ΠΎΠ΄Π° (Ρ 21 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½ Π±Π»ΡΡΠ΅ΡΠ½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π·, Ρ 9 β ΠΊΠ°ΠΏΠ»Π΅Π²ΠΈΠ΄Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π·), ΠΊΠΎΡΠΎΡΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° 2 Π³ΡΡΠΏΠΏΡ. Π ΠΏΠ΅ΡΠ²ΡΡ Π³ΡΡΠΏΠΏΡ Π²ΠΎΡΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Ρ Π²ΡΡΠ²Π»Π΅Π½Π½ΡΠΌΠΈ ΠΎΡΠ°Π³Π°ΠΌΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (18 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ), Π²ΠΎ Π²ΡΠΎΡΡΡ β Π±Π΅Π· Π½Π°Π»ΠΈΡΠΈΡ ΠΎΡΠ°Π³ΠΎΠ² Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (12 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ). ΠΡΡΠΏΠΏΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 15 ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΡ Π΄Π»Ρ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΊΠΎΠΆΠΈ. ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅, ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π° ΡΠ°ΠΊΠΆΠ΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΡΠ°ΠΌΠΌΠ°. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π½Π° ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΌ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠ΅ Cytomics FC500 ΡΠΈΡΠΌΡ Beckman Coulter Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΉ ΠΏΡΡΠΌΡΡ
ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΈ ΠΈΠ·ΠΎΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΉ. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π³ΡΡΠΏΠΏ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π΅ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ, ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΡΠΈΡΠ°Π»ΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΠΏΡΠΈ p 0,05.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΡΠΎ ΡΡΠΎΡΠΎΠ½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΠΈ ΠΌΠ°Π»ΡΡ
ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π’- ΠΈ Π-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ Π³ΡΡΠΏΠΏΠ° Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ, ΠΈΠΌΠ΅ΡΡΠΈΡ
ΠΠ₯Π, ΠΎΡΠ»ΠΈΡΠ°Π»Π°ΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (p = 0,034) ΠΈ Π’-Ρ
Π΅Π»ΠΏΠ΅ΡΠΎΠ² (p = 0,012), ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
CD3+HLA-DR+-ΠΊΠ»Π΅ΡΠΎΠΊ (p = 0,028 ΠΈ 0,036 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ), Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΡ
T-Ρ
Π΅Π»ΠΏΠ΅ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (p = 0,031). Π‘ΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡ ΡΡΠΎΠΏΠ½ΡΡ
ΠΊ ΠΊΠΎΠΆΠ΅ CLA+CD3+-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ Π±ΡΠ»Π° ΠΏΠΎΠ²ΡΡΠ΅Π½Π° ΠΊΠ°ΠΊ Π² ΠΏΠ΅ΡΠ²ΠΎΠΉ (p = 0,016), ΡΠ°ΠΊ ΠΈ Π²ΠΎ Π²ΡΠΎΡΠΎΠΉ (p = 0,044) Π³ΡΡΠΏΠΏΠ°Ρ
. Π’Π°ΠΊΠΆΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΈΡΡ ΠΎΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ°ΠΌΡΡΠΈ (p = 0,049 Π΄Π»Ρ 1-ΠΉ Π³ΡΡΠΏΠΏΡ, p = 0,003 Π΄Π»Ρ 2-ΠΉ Π³ΡΡΠΏΠΏΡ).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠ΅ ΠΎΡΠ°Π³ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΊ Π΄ΠΈΡΠ±Π°Π»Π°Π½ΡΡ Π² ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠΈ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ²: ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° CD3+CD4+ ΠΈ CD3+HLA-DR+ ΠΊΠ»Π΅ΡΠΎΠΊ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΡ
Π’-Ρ
Π΅Π»ΠΏΠ΅ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ. ΠΠ°Π½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΎΠ³ΡΡ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠ² ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° (ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅)
Background. The intestinal microbiota, on the one hand, protects a person from pathogens, on the other hand, it itself may be one of the triggers and/or mediators of progression in inflammatory bowel diseases. Inflammatory bowel disease (IBD) predominantly affects young people of working age. It noted a steady increase in the incidence of IBD in recent decades throughout the world and in Russia. Inflammatory bowel diseases significantly affect quality of life and lead to complications of having to perform surgery, which significantly reduces the quality of life. Aims of the study was to investigate the composition of the microbiota of the colon, the search features of the microbial spectrum of patients with inflammatory bowel disease patients compared with control patients. Materials and methods. A prospective study was carried out between patients with inflammatory bowel disease and patients without inflammatory bowel disease for the period 20182019. The study included 157 IBD patients and 150 patients without IBD. All patients studied stool, which have been subjected to microbiological and metagenomic study. Results. Most often, facultative anaerobic microorganisms were present in the stool of patients with IBD (in 60%, 103109 CFU/g) and in patients without IBD (69%, 103109 CFU/g), the share of gram-negative bacteria accounted for 52%, in mostly represented by bacilli belonging to the order Enterobacteriales, only 7% of isolated gram-negative facultative aerobic microorganisms were gram-negative non-fermenting bacteria represented by 5 genera: Acinetobacter, Burkholderia, Pseudomonas, Stenotrophomonas, Ralstonia. Gram-positive facultative anaerobic microorganisms in 89% were represented by cocci of the genus Enterococcus, Streptococcus, Staphylococcus, Micrococcus, Gemella, Globicatella, Granulicatella. Conclusions. According to the results of our study, special attention should be paid to the presence of rare microaerophilic and obligate anaerobic microorganisms in the fecal microbiota of patients with IBD (Arcobacter butzleri, Gardnerella vaginalis, Aromatoleum aromaticum, Terrisporobacter glycolicus (Clostridium glycolicum), Solobacterium moorei, Alloscardovia omnicolens, Fusobacterium nucleatum, Fusobacterium ulcerans, Dialister micraerophilus), that have not been isolated from patients without IBD. A timely adequate assessment of the composition and functional characteristics of the microbiota in terms of key biomarkers will make it possible to carry out targeted diagnostics and prevention of the immediate and long-term consequences of inflammatory bowel diseases.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΠ° ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°, Ρ ΠΎΠ΄Π½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ, Π·Π°ΡΠΈΡΠ°Π΅Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΎΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½ΠΎΠ², Π° Ρ Π΄ΡΡΠ³ΠΎΠΉ ΡΠ°ΠΌΠ° ΠΌΠΎΠΆΠ΅Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΡΡΠΈΠ³Π³Π΅ΡΠΎΠ² ΠΈ/ΠΈΠ»ΠΈ ΠΌΠ΅Π΄ΠΈΠ°ΡΠΎΡΠΎΠ² ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° (ΠΠΠ). ΠΠΠ ΠΏΠΎΡΠ°ΠΆΠ°ΡΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π»ΠΈΡ ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠ³ΠΎ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. ΠΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π½Π΅ΡΠΊΠ»ΠΎΠ½Π½ΡΠΉ ΡΠΎΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΠΠ Π² ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅ ΠΈ Π² Π ΠΎΡΡΠΈΠΈ. ΠΠΠ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ, Π° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΊ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ², ΡΡΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²Π° ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ, ΠΏΠΎΠΈΡΠΊ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ. ΠΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΡ
ΡΡ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅, Π±Π΅Π· Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π·Π° 20182019 Π³Π³. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 157 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΠΠ ΠΈ 150 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΠΠΠ. Π£ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈΡΡ Π±ΠΈΠΎΠΎΠ±ΡΠ°Π·ΡΡ ΡΡΡΠ»Π°, ΠΊΠΎΡΠΎΡΡΠ΅ Π±ΡΠ»ΠΈ ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π½ΡΡΡ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌΡ ΠΈ ΠΌΠ΅ΡΠ°Π³Π΅Π½ΠΎΠΌΠ½ΠΎΠΌΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π² ΠΏΡΠΎΡΠ²Π΅ΡΠ½ΡΡ
ΡΠ΅ΠΊΠ°Π»ΠΈΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ (Π² 60% ΡΠ»ΡΡΠ°Π΅Π² Π² ΡΠΈΡΡΠ΅ 103109 ΠΠΠ/Π³) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΠΠΠ (69% ΡΠ»ΡΡΠ°Π΅Π² Π² ΡΠΈΡΡΠ΅ 103109 ΠΠΠ/Π³) ΠΏΡΠΈΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ ΡΠ°ΠΊΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ Π°Π½Π°ΡΡΠΎΠ±Π½ΡΠ΅ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΡ, ΡΡΠ΅Π΄ΠΈ ΠΊΠΎΡΠΎΡΡΡ
Π½Π° Π΄ΠΎΠ»Ρ Π³ΡΠ°ΠΌΠ½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ ΠΏΡΠΈΡ
ΠΎΠ΄ΠΈΠ»ΠΎΡΡ 52% ΡΠ»ΡΡΠ°Π΅Π², Π² Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΠ°ΡΡΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΡ
Π±Π°ΡΠΈΠ»Π»Π°ΠΌΠΈ, ΠΎΡΠ½ΠΎΡΡΡΠΈΠΌΠΈΡΡ ΠΊ ΠΏΠΎΡΡΠ΄ΠΊΡ Enterobacteriales, ΡΠΎΠ»ΡΠΊΠΎ 7% ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π³ΡΠ°ΠΌΠ½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
ΡΠ°ΠΊΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ Π°ΡΡΠΎΠ±Π½ΡΡ
ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ²Π»ΡΠ»ΠΈΡΡ Π³ΡΠ°ΠΌΠ½Π΅Π³Π°ΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π΅ΡΠ΅ΡΠΌΠ΅Π½ΡΠΈΡΡΡΡΠΈΠΌΠΈ Π±Π°ΠΊΡΠ΅ΡΠΈΡΠΌΠΈ (ΠΠΠΠ€Π), ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΡΡΡ ΡΠΎΠ΄Π°ΠΌΠΈ: Acinetobacter, Burkholderia, Pseudomonas, Stenotrophomonas, Ralstonia. ΠΡΠ°ΠΌΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ°ΠΊΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ Π°Π½Π°ΡΡΠΎΠ±Π½ΡΠ΅ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΡ Π² 89% ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΊΠΎΠΊΠΊΠ°ΠΌΠΈ ΡΠΎΠ΄ΠΎΠ² Enterococcus, Streptococcus, Staphylococcus, Micrococcus, Gemella, Globicatella, Granulicatella. ΠΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ Π½Π°ΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΎΠ±ΡΠ°ΡΠΈΡΡ ΠΎΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π° ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π² ΡΠ΅ΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ ΡΠ΅Π΄ΠΊΠΈΡ
ΠΌΠΈΠΊΡΠΎΠ°ΡΡΠΎΡΠΈΠ»ΡΠ½ΡΡ
ΠΈ ΠΎΠ±Π»ΠΈΠ³Π°ΡΠ½ΠΎ Π°Π½Π°ΡΡΠΎΠ±Π½ΡΡ
ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ² Arcobacter butzleri, Gardnerella vaginalis, Aromatoleum aromaticum, Terrisporobacter glycolicus (Clostridium glycolicum), Solobacterium moorei, Alloscardovia omnicolens, Fusobacterium nucleatum, Fusobacterium ulcerans ΠΈ Dialister micraerophilus, ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π΅ Π±ΡΠ»ΠΈ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Ρ ΠΎΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΠΠΠ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘Π²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΎΡΡΠ°Π²Π° ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΠΊΠ»ΡΡΠ΅Π²ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΡ Π±Π»ΠΈΠΆΠ°ΠΉΡΠΈΡ
ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°
ΠΡΠ΅Π½ΠΊΠ° ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CLA+Π’-ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΊΡΠΎΠ²ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ
Background. CLA+T-cell are an important component of skin-associated lymphoid tissue, and thus determine the pathogenesis of many immuno-mediated dermatoses.
Aims. Determine the relative number of CLA+T-cell subpopulations in the peripheral blood of patients with psoriasis, lichen planus and atopic dermatitis, as well as assess their impact on the severity of dermatoses.
Materials and methods. We examined 82 patients with psoriasis aged 19 to 62 years, 54 patients with lichen planus (LP) aged 18 to 54 years, 44 patients with atopic dermatitis (AD) aged 18 to 44 years, as well as 20 practically healthy individuals aged 18 to 52 years who were admitted to the clinic for the removal of benign skin neoplasms.
All patients underwent a standard clinical examination with the determination of indicators that characterize the severity of dermatosis: PASI (Psoriasis Area and Severity Index) for patients with psoriasis, IPSLP (index of prevalence and severity of lichen planus) for patients with lichen planus and SCORAD (Scoring of Atopic Dermatitis) for patients with atopic dermatitis. Defining subpopulations CLA+T-lymphocytes were carried out on a flow cytometer Cytomics FC500 by Beckman Coulter using appropriate combinations of direct monoclonal antibodies and isotopic controls. The groups were compared using the nonparametric Mann Whitney test, and the differences were considered significant at p0,05. To analyze the relationship between the severity of dermatosis and the relative content of subpopulations CLA+T-cells used Spearman's rank correlation coefficient.
Results. In patients with psoriasis, a significant increase in the percentage of the total number of T-lymphocytes positive for CLA (CLA+CD3+) and T-helpers positive for CLA (CLA+CD4+) (p=0,002 and 8,5104, respectively), in patients with PL and AD only CLA+CD4+ lymphocytes (p=0,028 and 0,003, respectively). In the progressive period of psoriasis, a direct moderate correlation was found between the circulating subpopulation of cytotoxic T lymphocytes positive for CLA (CLA+CD8+) and the PASI index (rs=0,47; p0,001), in the acute period of AD between the CLA+CD3+ subpopulations and CLA+CD4+ cells and the SCORAD index (rs=0,53; p 0,001 and rs=0,57; p0,001, respectively). In PL, the severity of the course of dermatosis was not accompanied by any significant changes in the CLA-positive T-cell subpopulations.
Conclusion. The results of the study confirmed the important role of CLA+T cell subpopulations in the development of chronic dermatoses. In all groups (psoriasis, LP and AD), an increase in the relative number of CLA+CD4+ T-helpers was noted compared with the control group. The relationship between the severity of psoriasis and the relative number of CLA+CD8+ cytotoxic T-lymphocytes, and the severity of AD with CLA+CD3+ and CLA+CD4+ T-helpers is also shown.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. CLA+Π’-ΠΊΠ»Π΅ΡΠΊΠΈ ΡΠ²Π»ΡΡΡΡΡ Π²Π°ΠΆΠ½ΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ ΠΊΠΎΠΆΠ΅ΠΉ, Π° Π·Π½Π°ΡΠΈΡ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π· ΠΌΠ½ΠΎΠ³ΠΈΡ
ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ².
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CLA+T-ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ, ΠΏΠ»ΠΎΡΠΊΠΈΠΌ Π»ΠΈΡΠ°Π΅ΠΌ (ΠΊΡΠ°ΡΠ½ΡΠΌ ΠΏΠ»ΠΎΡΠΊΠΈΠΌ Π»ΠΈΡΠ°Π΅ΠΌ) ΠΈ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΡΠΆΠ΅ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ².
ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 82 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 19 Π΄ΠΎ 62 Π»Π΅Ρ, 54 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠ»ΠΎΡΠΊΠΈΠΌ Π»ΠΈΡΠ°Π΅ΠΌ (ΠΠ) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 18 Π΄ΠΎ 54 Π»Π΅Ρ, 44 Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ (ΠΠ) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 18 Π΄ΠΎ 44 Π»Π΅Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ 20 ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 18 Π΄ΠΎ 52 Π»Π΅Ρ, ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΡ Π΄Π»Ρ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΊΠΎΠΆΠΈ.
ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡΠΆΠ΅ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ²: PASI (Psoriasis Area and Severity Index) Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ, ΠΠ Π’ΠΠ (ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΏΠ»ΠΎΡΠΊΠΎΠ³ΠΎ Π»ΠΈΡΠ°Ρ) Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠ»ΠΎΡΠΊΠΈΠΌ Π»ΠΈΡΠ°Π΅ΠΌ ΠΈ SCORAD (Scoring of Atopic Dermatitis) Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CLA+Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π½Π° ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΌ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠ΅ Cytomics FC500 ΡΠΈΡΠΌΡ Beckman Coulter Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΉ ΠΏΡΡΠΌΡΡ
ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΈ ΠΈΠ·ΠΎΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΉ. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π³ΡΡΠΏΠΏ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π΅ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΠΠ°Π½Π½Π° Π£ΠΈΡΠ½ΠΈ, ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΡΠΈΡΠ°Π»ΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΠΏΡΠΈ p0,05. ΠΠ»Ρ Π°Π½Π°Π»ΠΈΠ·Π° Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΡΠΆΠ΅ΡΡΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ² ΠΈ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CLA+Π’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ ΡΠ°Π½Π³ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π‘ΠΏΠΈΡΠΌΠ΅Π½Π°.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΏΠΎ CLA (CLA+CD3+), ΠΈ Π’-Ρ
Π΅Π»ΠΏΠ΅ΡΠΎΠ², ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΏΠΎ CLA (Π‘LA+CD4+) (p=0,002 ΠΈ 8,5104 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ), Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ ΠΈ ΠΠ ΡΠΎΠ»ΡΠΊΠΎ CLA+CD4+ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (p=0,028 ΠΈ 0,003 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅ΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΏΡΡΠΌΠ°Ρ ΡΠΌΠ΅ΡΠ΅Π½Π½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠ΅ΠΉ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΏΠΎ CLA (CLA+CD8+), ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ PASI (rs=0,47; p0,001), Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΠ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΠΌΠΈ CLA+CD3+ ΠΈ CLA+CD4+ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ SCORAD (rs=0,53; p0,001 ΠΈ rs=0,57; p0,001 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΡΠΈ ΠΠ ΡΡΠΆΠ΅ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π° Π½Π΅ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π»Π°ΡΡ ΠΊΠ°ΠΊΠΈΠΌΠΈ-Π»ΠΈΠ±ΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΠΌΠΈ ΡΠΎ ΡΡΠΎΡΠΎΠ½Ρ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π’-ΠΊΠ»Π΅ΡΠΎΠΊ, ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΏΠΎ CLA.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»ΠΈ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CLA+Π’-ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ². ΠΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
(ΠΏΡΠΎΡΠΈΠ°Π·, ΠΠ ΠΈ ΠΠ) ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° CLA+CD4+ Π’-Ρ
Π΅Π»ΠΏΠ΅ΡΠΎΠ² ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ. Π’Π°ΠΊΠΆΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΡΡΠΆΠ΅ΡΡΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° Ρ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ CLA+CD8+ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π° ΡΡΠΆΠ΅ΡΡΠΈ ΠΠ Ρ CLA+CD3+ ΠΈ CLA+CD4+ Π’-Ρ
Π΅Π»ΠΏΠ΅ΡΠ°ΠΌΠΈ